A clinical trial of simvastatin in postmenopausal female patients with osteoporosis [38], [39] demonstrated the ability of simvastatin to increase new bone formation [40], while an in vitro study characterized the mechanisms through which simvastatin (2.5 μM) increases expression of the BMP-2 gene in bone cells [40]. The gene discussed is BMP2; the disease is osteoporosis.